Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanjing Vishee Medical Technology Co., Ltd (688580.SS)
Nanjing, CN
Nanjing Vishee Medical Technology Co., Ltd. is a Chinese firm dedicated to creating and manufacturing a range of medical rehabilitation equipment. Their offerings encompass therapeutic solutions for pelvic floor and postpartum recovery, neurological conditions, and mental health challenges. Additionally, the company provides advanced bio-stimulation feedback instruments and magnetic stimulators. These technologies address diverse areas, including electrical and magnetic stimulation, electrophysiology, and other specialized technical fields. Nanjing Vishee distributes its products to hospitals and various medical and professional end-users primarily through its network of authorized dealers and sales channels. Established in 2001, the company's headquarters are located in Nanjing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.52% | -11.02% | -19.86% | -12.03% | +13.86% | +6.40% | +11.26% | -10.00% | -50.62% | -71.55% | -71.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+15.7% ★ Q1'26: +10.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+34.6% ★ Q1'26: +82.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+29.4% ★ Q1'26: -58.7% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+28.5% ★ Q1'26: +28.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+17.6% ★ Q1'26: +12.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
378.37M
est: 378.00M (+0.1%)
|
430.04M
est: 430.00M (+0.0%)
|
321.62M
est: 326.92M (-1.6%)
|
462.22M
est: 434.00M (+6.5%)
|
400.06M
est: 420.00M (-4.7%)
|
462.73M
est: 468.37M (-1.2%)
|
560.32M
560.32M – 560.32M
+19.6% YoY
|
639.05M
639.05M – 639.05M
+14.1% YoY
|
727.00M
726.00M – 728.00M
+13.8% YoY
|
| EBITDA |
175.29M
est: 155.37M (+12.8%)
|
207.46M
est: 176.74M (+17.4%)
|
122.13M
est: 134.37M (-9.1%)
|
170.28M
est: 166.25M (+2.4%)
|
134.68M
est: 160.89M (-16.3%)
|
161.11M
est: 179.42M (-10.2%)
|
214.64M
214.64M – 214.64M
+19.6% YoY
|
244.80M
244.80M – 244.80M
+14.1% YoY
|
278.49M
278.11M – 278.87M
+13.8% YoY
|
| EBIT |
166.49M
est: 139.38M (+19.5%)
|
197.57M
est: 158.56M (+24.6%)
|
106.17M
est: 120.55M (-11.9%)
|
151.33M
est: 146.54M (+3.3%)
|
114.59M
est: 141.81M (-19.2%)
|
131.82M
est: 158.14M (-16.6%)
|
189.19M
189.19M – 189.19M
+19.6% YoY
|
215.77M
215.77M – 215.77M
+14.1% YoY
|
245.47M
245.13M – 245.81M
+13.8% YoY
|
| Net Income |
143.66M
est: 143.42M (+0.2%)
|
177.81M
est: 177.70M (+0.1%)
|
93.83M
est: 102.71M (-8.7%)
|
136.26M
est: 115.51M (+18.0%)
|
101.97M
est: 120.39M (-15.3%)
|
138.07M
est: 134.72M (+2.5%)
|
170.84M
170.84M – 170.84M
+26.8% YoY
|
197.40M
197.40M – 197.40M
+15.5% YoY
|
228.36M
228.36M – 228.36M
+15.7% YoY
|
| SGA |
104.99M
est: 89.04M (+17.9%)
|
115.63M
est: 101.29M (+14.2%)
|
129.20M
est: 77.01M (+67.8%)
|
151.82M
est: 125.86M (+20.6%)
|
138.41M
est: 121.80M (+13.6%)
|
48.59M
est: 135.83M (-64.2%)
|
162.50M
162.50M – 162.50M
+19.6% YoY
|
185.33M
185.33M – 185.33M
+14.1% YoY
|
210.83M
210.54M – 211.12M
+13.8% YoY
|
| EPS |
1.76
est: 1.50 (+17.3%)
|
1.86
est: 1.86 (+0.1%)
|
0.98
est: 1.07 (-8.8%)
|
1.43
est: 1.21 (+18.3%)
|
1.07
est: 1.26 (-15.1%)
|
1.44
est: 1.41 (+2.1%)
|
1.79
1.79 – 1.79
+26.8% YoY
|
2.07
2.07 – 2.07
+15.5% YoY
|
2.39
2.39 – 2.39
+15.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.90% | 634.2K | 0.95% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Lili | Deputy GM, Chief Financial Officer & Director | — | female |
| Chuan Han | Deputy General Manager | — | male |
| Fei Gao | R&D Director and Core Technician | — | male |
| Kai Qiu | Deputy General Manager | — | male |
| Wenjing Yao | Accounting Supervisor | — | — |
| Wenlong Liu | Marketing Director | — | male |
| Yihong Tong | Senior Director of Strategic Investment Department & Secretary of the Board | — | female |
| Zhang Hui | Deputy GM & Director | — | male |
| Zhiyu Wang | GM & Chairman of the Board | — | male |
| Zhong Yiqun | Deputy General Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688580.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
